Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Last U.S. amoxicillin maker urges long‑term federal contracts to secure supply
Summary
Patrick Cashman, president of US Antibiotics, told a House subcommittee that his Bristol, Tennessee plant is the only U.S. end‑to‑end manufacturer of amoxicillin and asked Congress for predictable purchasing, buy‑American rules and a strategic manufacturing fund to prevent future shortages.
Patrick Cashman, president of US Antibiotics, told the House Energy and Commerce Subcommittee on Health that his Bristol, Tennessee facility is the last end‑to‑end U.S. maker of amoxicillin and urged federal policy changes to keep that capacity operating.
Cashman said US Antibiotics supplies a product that accounts for roughly 50 million U.S. prescriptions annually and that the company now has about a 5% market share after investors reactivated production. He warned that if the plant were to close permanently it would take “no less than 5 years and hundreds of millions of dollars to construct a new facility capable of producing amoxicillin.”
Why it matters: witnesses and members described…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
